Portal Hypertension - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Portal Hypertension - Pipeline Review, H2 2016

Portal Hypertension - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Portal Hypertension - Pipeline Review, H2 2016
Published Aug 31, 2016
69 pages — Published Aug 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Portal Hypertension - Pipeline Review, H2 2016, provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
- The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and

  
Source:
Document ID
GMDHC8425IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Portal Hypertension Overview61
Therapeutics Development71
  Pipeline Products for Portal Hypertension Overview71
Portal Hypertension Therapeutics under Development by Companies81
Portal Hypertension Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Portal Hypertension Products under Development by Companies111
Portal Hypertension Companies Involved in Therapeutics Development126
  Conatus Pharmaceuticals Inc.121
  Cumberland Pharmaceuticals, Inc.131
  Galectin Therapeutics, Inc.141
  Genextra S.p.a.151
  LinXis B.V.161
  Mezzion Pharma Co. Ltd.171
Portal Hypertension Therapeutics Assessment189
  Assessment by Monotherapy Products181
  Assessment by Target192
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Drug Profiles2733
  emricasan Drug Profile276
  GRMD-02 Drug Profile3311
  ifetroban sodium Drug Profile442
  LIN-003 Drug Profile461
  obeticholic acid Drug Profile4710
  udenafil Drug Profile573
Portal Hypertension Dormant Projects601
Portal Hypertension Discontinued Products611
Portal Hypertension Product Development Milestones626
  Featured News &Press Releases621
    Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting621
    ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis622
    Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting641
    Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting651
    Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension651
    Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting662
Appendix682
  Methodology681
  Coverage681
  Secondary Research681
  Primary Research681
  Expert Panel Validation681
  Contact Us681
  Disclaimer691

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Portal Hypertension - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. May 14, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Portal-Hypertension-Pipeline-Review-H2-2016-2088-16508>
  
APA:
Global Markets Direct - Market Research. (2016). Portal Hypertension - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Portal-Hypertension-Pipeline-Review-H2-2016-2088-16508>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.